Thursday, June 1, 2017

2017 June Newsletters: A Review of Current HCV Therapies, Gilead's New Combo & Blog Updates

June Newsletters: A Review of Current HCV Therapies,  Gilead's New Combo & Blog Updates
The month of June has arrived, a time for picnics, family and friends. Greetings everyone, welcome to this months index of Newsletters, filled with useful, relevant information about viral hepatitis. In addition enjoy recent articles written by a small list of dedicated bloggers.

Hot Off The Press
HCV Advocate does it again! In a two part series; part one was published in May, part two available in this months newsletter, the peoples website is all about key data presented in April at the International Liver Congress. Read about treating HCV genotype 3, or treatment in experienced patients with sofosbuvir/velpatasvir plus voxilaprevir.

Other Updates
U.S. National Library of Medicine today released; Hepatitis C in a New Era: A Review of Current Therapies, an easy to read summary of newly available HCV treatment regimens.

Investigational Drugs
Published in the New England Journal of Medicine is an original article reporting on two, phase 3 trials using Gilead's sofosbuvir (Sovaldi), velpatasvir and voxilaprevir. A link to the full text article is here, provided by Henry E. Chang via Twitter. Read more on the trials in News & Perspective at Medscape. If reading all that clinical stuff isn't your thing, here is a more patient-friendly, short and to the point article, from HealthDay News.

This past December Gilead submitted a New Drug Application (NDA) to  the U.S. Food and Drug Administration for SOF/VEL/VOX. The data submitted in the NDA support the use of the regimen for 12 weeks in DAA-experienced patients with genotype 1 to 6 HCV infection without cirrhosis or with compensated cirrhosis.

June Newsletters

HCV Advocate
The HCV Advocate newsletter is a valuable resource designed to provide the hepatitis C community with monthly updates on events, clinical research, and education.


Alan’s coverage includes: final results from a phase 3 study of glecaprevir plus pibrentasvir (one pill/once-a-day) to treat genotype 3; a phase 2 study of MK-3682/grazoprevir plus ruzasvir to treat people who previously failed direct-acting antiviral therapy; treatment with sofosbuvir/velpatasvir plus voxilaprevir (one-pill, once-a-day) in treatment experienced patients with resistance and finally a study comparing liver cancer outcomes in people achieving a cure with interferon-based therapies vs. direct-acting antiviral therapies.

Lucinda’s coverage includes: high cure rates with legally imported generic HCV drugs; Harvoni in patients with HCV/HBV coinfection; Harvoni +/– ribavirin treatment in children with chronic hepatitis C and lastly physical activity and cardiorespiratory fitness levels in people living with hepatitis C.

Matthew’s coverage includes: a study of a viral load point-of-care test that has the potential to improve the HCV treatment cascade and the long-term gender differences in outcomes among people with hepatitis B and hepatitis C.

The Drug Pipeline is be updated on a monthly basis and is always included with the HCV Advocate Newsletter

What’s Up! Have you listened to our new voiceovers? We have added voiceovers to some of our most popular Easy C fact sheets – check them out!

Quick Links

HCV Action - UK
HCV Action brings together hepatitis C health professionals from across the patient pathway with the pharmaceutical industry and patient representatives to share expertise and good practice. 
New hepatitis C treatment made available in UK via Early Access to Medicines Scheme

Weekly Bull
HepCBC is a non-profit organization run by and for people infected and affected by hepatitis C. Our mission is to provide education, prevention and support to those living with HCV.

Weekly Newsletter
Latest Issue: Weekly Bull

The National Viral Hepatitis Roundtable NVHR
The National Viral Hepatitis Roundtable is a broad coalition working to fight, and ultimately end, the hepatitis B and hepatitis C epidemics. We seek an aggressive response from policymakers, public health officials, medical and health care providers, the media, and the general public through our advocacy, education, and technical assistance.

The National Viral Hepatitis Roundtable, Hep B United, NASTAD, and CDC’s Division of Viral Hepatitis will be hosting a Twitter chat on Thursday, June 8th at 2 pm Eastern Time. We're inviting you to join us! The #HepChat will highlight activities that hepatitis B and C partner organizations conducted during Hepatitis Awareness Month.

Save the Date: Congressional briefing on hepatitis B and C elimination
NVHR, AASLD, Hep B United, and NASTAD are hosting a Congressional briefing on hepatitis B and C elimination on June 15, 2017.

Read all newsletters, here.

British Liver Trust
The British Liver Trust is the leading UK liver disease charity for adults – we provide information and support; increase awareness of how liver disease can be prevented and promote early diagnosis; fund and champion research and campaign for better services.

At the moment three quarters of people are diagnosed with liver disease in a hospital setting when they already have cirrhosis – which can be too late. Love Your Liver aims to change this by raising awareness of the risk factors of liver disease and improving early diagnosis...

Past newsletters, here.

The New York City Hepatitis C Task Force
The New York City Hepatitis C Task Force is a city-wide network of service providers and advocates concerned with hepatitis C and related issues. The groups come together to learn, share information and resources, network, and identify hepatitis C related needs in the community. Committees form to work on projects in order to meet needs identified by the community.

Stay Updated

GI & Hepatology News
Over 17,000 gastroenterologists and hepatologists rely on GI & Hepatology News every month to cover the world of medicine with breaking news, on-site medical meeting coverage, and expert perspectives both in print and online. The official newspaper of the AGA Institute was launched in partnership with IMNG in January 2007.

June 2017                 

Liver Disease
In The News
Review all newsletters, here
New from CDC
CONNECTIONS A Bimonthly e-Newsletter - May - June 2017 - CDC

Blog Updates From Around The Web

Hepatitis B Foundation
The Hepatitis B Foundation is a national nonprofit organization dedicated to finding a cure for hepatitis B and helping to improve the lives of those affected worldwide through research, education and patient advocacy. Our monthly electronic newsletter, provides research updates, healthy liver tips, information on public health initiatives, and other HBF news.
Click here to subscribe

Blog Updates
When Can Hepatitis B Patients Stop Taking Antivirals? Experts Finally Have Some Answers
By Christine Kukka
With the help of antivirals, many patients today have undetectable viral load (HBV DNA), a relatively healthy liver and cleared the hepatitis B “e” antigen (HBeAg). So when can they consider stopping their daily entecavir or tenofovir pill?

View all updates, here.

At we empower patients and caregivers to take control of Hepatitis C by providing a platform to learn, educate, and connect with peers and healthcare professionals

Blog Updates
Awareness Month 2017 Recap
At, we just want to thank everyone, from our writers to our community members, for their help spreading awareness during Hepatitis Awareness Month. In case you missed it, we wanted to...

Inspiration Comes In Many Forms
What inspires you? I know it is a broad question that can mean so many things to different people. Some speak of inspiration in terms of religious faith, while others see it...

View all blog updates, here.


Hep BOOMers
Hep BOOMers is dedicated to the millions of Baby Boomers who contracted hepatitis C and to the boom in medical research that could cure them.

Blog Updates
Book about Hepatitis C now available, will talk about Demon in My Blood at May & June events
The book tells the story of my bout with hepatitis C, my cure, the development of direct-acting antivirals, the accessibility of the drugs, and the quest to learn how I acquired the disease. Demon in My Blood can be read as a history of medical innovation, a patient-experience chronicle, or a mystery. It’s also a cry for widespread testing.

Read all updates, here

HEP - Blog Updates
Hep is an award-winning print and online brand for people living with and affected by viral hepatitis. Offering unparalleled editorial excellence since 2010, Hep and Hep Magazine are the go-to source for educational and social support for people living with hepatitis.

Blog Updates
Angels and Devils
By Greg Jefferys
Each day I receive 50 or 60 emails from all around the world. Some people asking for help, some people thanking me for the little bit of help I was able to give.

One Minute at a Time
Karen Hoyt blogs about life after hepatitis C, cirrhosis, end-stage liver disease, liver cancer, and liver transplantation.
By Karen Hoyt
It’s a busy and wonderful life I lead. Making every minute count is a way to honor my Creator, my donor, and myself.

Remembering our Veterans With Hepatitis C
Approximately 5.4 percent of military veterans in the United States are infected with chronic hepatitis C. This is triple that of the general population. Approximately 174,000 veterans under care of the Veterans Health Administration (VHA) have confirmed chronic hepatitis C. Veterans with the highest risks for hepatitis C are those who served in the Vietnam War era, those with alcohol or substance use disorders, and those with psychiatric conditions or homelessness.

To view a list of all bloggers please click here.

Creating a World Free of Hepatitis C
Welcome to my website and blog. My name is Lucinda Porter and I am a nurse committed to raising awareness about hepatitis C. I believe that we can create a world free of hepatitis C. We do this together, one step at a time.

Blog Updates
Helping Your Brain
Last week, I blogged about forgetfulness. This week, I provide some tips on how to keep your brain healthy. Just because memory decline is natural does not mean we can’t help slow down the process. The brain is like a muscle in that if you don’t use it you lose it. An active brain can grow new cells and work more effectively.

MD Whistleblower
Michael Kirsch, M.D.
I am a full time practicing physician and writer. I write about the joys and challenges of medical practice including controversies in the doctor-patient relationship, medical ethics and measuring medical quality. When I'm not writing, I'm performing colonoscopies.

Blog Updates
Should Physicians Provide Futile Care?
I was covering for my partner over the weekend and saw his patient with end stage liver disease, a consequence of decades of alcohol abuse.  He was one of the most deeply jaundiced individuals I have ever seen.  His mental status was still preserved.  He could converse and responded appropriately to my routine inquiries, although he was somewhat sluggish in his thinking.  It’s amazing that even after the majority of a liver is dead, that a person can still live.

View additional blog updates, here.

Healthy You
New research from the Westmead Institute's Storr Liver Centre in collaboration with the Centre for Virus Research and Kirby Institute has shown that serum zinc may benefit liver disease in a way we never expected.

In a recent systematic review coffee consumption was associated with a reduced risk for developing primary liver cancer (Hepatocellular Carcinoma).

Until next time.

No comments:

Post a Comment